Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
103.85
+0.76 (+0.74%)
Official Closing Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,528,050
Open
103.16
Bid (Size)
101.18 (1)
Ask (Size)
103.90 (1)
Prev. Close
103.09
Today's Range
103.03 - 103.93
52wk Range
92.35 - 120.92
Shares Outstanding
N/A
Dividend Yield
3.64%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
Today 10:17 EST
Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, and a promising innovation pipeline.
Via
Benzinga
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
November 12, 2024
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3...
Via
Benzinga
Performance
YTD
+2.82%
+2.82%
1 Month
-9.16%
-9.16%
3 Month
-11.81%
-11.81%
6 Month
+2.71%
+2.71%
1 Year
+6.96%
+6.96%
More News
Read More
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
Via
Investor's Business Daily
Is NYSE:NVS suited for dividend investing?
November 01, 2024
Via
Chartmill
Novartis Reports Q3 Momentum, But Shares Lose Support
October 29, 2024
Via
Investor's Business Daily
Looking Into Novartis's Recent Short Interest
October 14, 2024
Via
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Via
Benzinga
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
October 30, 2024
Via
Benzinga
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
October 29, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook
October 29, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
Why NYSE:NVS is a Top Pick for Dividend Investors.
October 09, 2024
Via
Chartmill
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
October 28, 2024
Via
Investor's Business Daily
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
October 28, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
October 28, 2024
Via
Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
Via
The Motley Fool
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
October 18, 2024
Via
Benzinga
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
October 18, 2024
Via
Benzinga
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
October 17, 2024
Via
The Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
Via
Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
October 14, 2024
Via
The Motley Fool
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm
October 10, 2024
Via
Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
Via
Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
Via
FinancialNewsMedia
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
October 03, 2024
Via
Investor's Business Daily
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.